Corvus Pharmaceuticals IncNASDAQ:CRVS
- LAST PRICE1.4500
- TODAY'S CHANGE (%)-0.0200 (-1.3605%)
- Bid / Lots1.3500/ 5
- Ask / Lots1.6700/ 1
- Open / Previous Close1.4600 / 1.4700
- Day Range
- 52 Week Range
- Volume45,642
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRVS |
|---|---|---|
| 09:32 ET | 1127 | 1.42 |
| 09:41 ET | 7065 | 1.5097 |
| 10:12 ET | 100 | 1.44 |
| 10:37 ET | 837 | 1.49 |
| 10:44 ET | 280 | 1.51 |
| 10:46 ET | 455 | 1.495 |
| 10:48 ET | 675 | 1.5099 |
| 10:51 ET | 200 | 1.48 |
| 10:53 ET | 100 | 1.49 |
| 10:55 ET | 1250 | 1.5 |
| 11:02 ET | 335 | 1.49 |
| 11:15 ET | 400 | 1.4601 |
| 12:05 ET | 4980 | 1.44 |
| 12:09 ET | 5000 | 1.4465 |
| 01:03 ET | 100 | 1.465 |
| 01:06 ET | 381 | 1.45 |
| 01:08 ET | 300 | 1.45 |
| 01:10 ET | 500 | 1.45 |
| 01:17 ET | 400 | 1.43 |
| 01:28 ET | 500 | 1.43 |
| 01:42 ET | 3100 | 1.43 |
| 01:53 ET | 1200 | 1.44 |
| 02:08 ET | 857 | 1.43 |
| 02:18 ET | 1024 | 1.44 |
| 02:24 ET | 400 | 1.4433 |
| 02:38 ET | 100 | 1.46 |
| 03:05 ET | 1000 | 1.4401 |
| 03:07 ET | 120 | 1.4639 |
| 03:16 ET | 100 | 1.455 |
| 03:18 ET | 100 | 1.47 |
| 03:27 ET | 100 | 1.465 |
| 03:34 ET | 1298 | 1.465 |
| 03:43 ET | 100 | 1.4565 |
| 03:56 ET | 404 | 1.45 |
| 03:57 ET | 236 | 1.45 |
| 03:59 ET | 4282 | 1.45 |
Sep 7, 2023
DJ Corvus Pharmaceuticals Price Target Maintained With a $4.00/Share by Cantor Fitzgerald, from 10:53AM ET on Thursday Sep 07, 2023 by Dow Jones
10:53AM ET on Thursday Sep 07, 2023 by Dow Jones
Sep 6, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Corvus Pharmaceuticals Inc | 72.0M | -1.7x | --- |
Eliem Therapeutics Inc | 71.2M | -1.5x | --- |
Kronos Bio Inc | 72.9M | -0.6x | --- |
Cardiff Oncology Inc | 72.4M | -1.8x | --- |
AVROBIO Inc | 69.5M | -11.1x | --- |
Athira Pharma Inc | 74.6M | -0.7x | --- |
Company Information
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of immune modulator product candidates with the potential to treat solid cancers, T cell lymphomas, autoimmune, allergic and infectious diseases. Its lead product candidate is CPI-818, a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T cell lymphomas. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. Its third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Its product candidate also includes CPI-182, an Anti-CXCR2 Antibody designed to block inflammation and myeloid suppression.
Contact Information
- Headquarters
- 863 Mitten Rd Ste 102BURLINGAME, CA, United States 94010-1311
- Phone
- 650-900-4520
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Richard Miller
- Chief Financial Officer
- Leiv Lea
- Senior Vice President - Pharmaceutical Development
- William Jones
- Independent Director
- Ian Clark
- Independent Director
- Elisha Gould
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $72.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-0.84 |
Book Value | $1.21 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
